ChamlinSL, ChrenMM. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):281–288; doi: 10.1016/j.iac.2010.05.004
2.
McCannMR, KosloskiMP, XuC, et al.Dupilumab: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8):e13899; doi: 10.1111/cts.13899
3.
JhaMK, HanY, LiuZ, et al.Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch. J Allergy Clin Immunol. 2025;156(4):1066–1081.e12; doi: 10.1016/j.jaci.2025.05.011
4.
FerreiraS, TorresT. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs Context. 2020;9:2020–2022-3; doi: 10.7573/dic.2020-2-3
5.
LicataG, TancrediV, CalabreseG, et al.Atopic dermatitis and difficult-to-treat areas: A case series of four patients with dupilumab-resistant primary atopic blepharitis and successfully treated with upadacitinib. Dermatitis. 2024;35(4):409–410; doi: 10.1089/derm.2023.0196
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
